MaxCyte (NASDAQ:MXCT) Posts Earnings Results, Beats Estimates By $0.04 EPS

MaxCyte (NASDAQ:MXCT) released its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04, Zacks reports. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%.

MaxCyte Trading Up 1.5 %

Shares of MXCT stock traded up $0.05 during trading on Tuesday, hitting $3.47. The company’s stock had a trading volume of 569,560 shares, compared to its average volume of 592,048. The company has a market cap of $367.68 million, a PE ratio of -10.21 and a beta of 1.35. The business has a fifty day moving average of $4.25 and a 200-day moving average of $4.00. MaxCyte has a 52 week low of $3.16 and a 52 week high of $5.26.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.